# FLAG Therapeutics — WebsDocs ASG Directory Profile

This is a public business listing published by the WebsDocs ASG Directory.
It provides machine-readable public information and static answers. It is not a live seller AI.



Canonical Directory profile:
https://directory.websdocs.com/business/flag-therapeutics

Canonical Directory JSON:
https://directory.websdocs.com/business/flag-therapeutics.json

Machine-readable public profile:
https://aig.websdocs.com/ai/flag-therapeutics/profile

Company profile JSON:
https://aig.websdocs.com/ai/flag-therapeutics/data/aig-company-profile.json

Static Agent Card:
https://aig.websdocs.com/ai/flag-therapeutics/.well-known/agent-card.json

Public discovery endpoints:
- Profile: https://aig.websdocs.com/ai/flag-therapeutics/profile
- Company JSON: https://aig.websdocs.com/ai/flag-therapeutics/data/aig-company-profile.json
- Services: https://aig.websdocs.com/ai/flag-therapeutics/services
- Offers: https://aig.websdocs.com/ai/flag-therapeutics/offers
- Schema: https://aig.websdocs.com/ai/flag-therapeutics/schema.jsonld
- Agent Card: https://aig.websdocs.com/ai/flag-therapeutics/.well-known/agent-card.json

Business summary:
FLAG-003, the company’s lead candidate for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG - a rare and fatal pediatric cancer) and glioblastoma multiform (GBM), is on-track to enter Phase 1 clinical development in early 2026 in children with DIPG. Raleigh, North Carolina Info@FlagTherapeutics.com 919.294.6472 Privacy Policy Contact Us

Status and boundaries:
- Directory public profile
- Customer-owned domain required: not applicable
- Active seller agent: false
- A2A messaging: unavailable
- Live reasoning or RAG: unavailable
- UCP and MCP: unavailable
- Checkout and payment execution: unavailable
- Private data access: unavailable

Use the canonical Directory profile for current public evidence.  Do not infer that a live AI Sales Gateway is active.